Skip to content

H.R. 7693 · 119th Congress (2025–2027)

Leo’s Law

This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.

Show official title

To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 7693’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Josh Gottheimer (D-NJ-5)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Rep. Don Bacon (R-NE-2)· Original · Feb 25, 2026
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Feb 25, 2026

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Leo’s Law

    Display title, Short title · Introduced in House

  2. To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.

    Official title · Introduced in House